TISIDB

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform Long: Cell membrane Single-pass type I membrane protein Extracellular side Note=Localized at the cell surface of melanoma cells.; SUBCELLULAR LOCATION: Isoform Short: Secreted, extracellular space, extracellular matrix. Cell surface. Note=Localized at the cell surface of melanoma cells.
Domain	PF11857 Domain of unknown function (DUF3377) PF00045 Hemopexin PF00413 Matrixin PF01471 Putative peptidoglycan binding domain
Function	Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001503 ossification GO:0001958 endochondral ossification GO:0016485 protein processing GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0030574 collagen catabolic process GO:0032963 collagen metabolic process GO:0035988 chondrocyte proliferation GO:0036075 replacement ossification GO:0043062 extracellular structure organization GO:0044236 multicellular organism metabolic process GO:0044243 multicellular organism catabolic process GO:0044259 multicellular organismal macromolecule metabolic process GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048701 embryonic cranial skeleton morphogenesis GO:0048704 embryonic skeletal system morphogenesis GO:0048705 skeletal system morphogenesis GO:0048706 embryonic skeletal system development GO:0051604 protein maturation GO:0060348 bone development GO:0060349 bone morphogenesis GO:0060350 endochondral bone morphogenesis GO:0097094 craniofacial suture morphogenesis GO:1904888 cranial skeletal system development
Molecular Function	GO:0004175 endopeptidase activity GO:0004177 aminopeptidase activity GO:0004222 metalloendopeptidase activity GO:0008047 enzyme activator activity GO:0008235 metalloexopeptidase activity GO:0008237 metallopeptidase activity GO:0008238 exopeptidase activity GO:0070006 metalloaminopeptidase activity
Cellular Component	GO:0005578 proteinaceous extracellular matrix GO:0005796 Golgi lumen

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1592389: Activation of Matrix Metalloproteinases R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1474244: Extracellular matrix organization

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MMP16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MMP16 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MMP16 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.781	0.314
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.224	0.36
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.453	0.68
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.205	0.0102
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.186	0.364
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.234	0.405
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.589	0.505
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-1.242	0.42
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	2.694	0.0899
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.196	0.763
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.144	0.865
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.111	0.55

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MMP16 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	21.4	5.9	15.5	0.304
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	30	0	30	0.528
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	4.1	3.3	0.61
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	11.1	-8.5	0.299
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	14.3	-14.3	0.209
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MMP16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MMP16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MMP16. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MMP16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MMP16 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MMP16 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MMP16
Name	matrix metallopeptidase 16 (membrane-inserted)
Aliases	MT3-MMP; DKFZp761D112; C8orf57; matrix metalloproteinase 16 (membrane-inserted); chromosome 8 open reading f ......
Chromosomal Location	8q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MMP16 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting MMP16.

ID	Name	Drug Type	Targets	#Targets
DB00786	Marimastat	Small Molecule	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP1 ......	23
DB03880	Batimastat	Small Molecule	ADAM28, ADAMTS5, MMP12, MMP16, MMP8	5

Browse MMP16